LivaNova (NASDAQ:LIVN) Reaches New 52-Week High – Should You Buy?

LivaNova PLC (NASDAQ:LIVN) shares reached a new 52-week high on Thursday . The company traded as high as $81.71 and last traded at $80.7470, with a volume of 38220 shares traded. The stock had previously closed at $79.95.

Wall Street Analyst Weigh In

A number of analysts have commented on LIVN shares. Robert W. Baird cut their price objective on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. KeyCorp boosted their target price on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Barclays lifted their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Finally, Mizuho boosted their price objective on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $80.75.

LivaNova Trading Up 2.9%

The stock has a market cap of $4.58 billion, a PE ratio of 42.76 and a beta of 0.88. The company’s 50-day moving average price is $72.20 and its 200 day moving average price is $66.92. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same period in the prior year, the business posted $0.88 earnings per share. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts forecast that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director owned 7,228 shares of the company’s stock, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.35% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Large investors have recently made changes to their positions in the stock. Hantz Financial Services Inc. boosted its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares during the period. State of Wyoming purchased a new stake in LivaNova in the second quarter valued at approximately $31,000. EverSource Wealth Advisors LLC lifted its stake in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares in the last quarter. Quarry LP acquired a new position in LivaNova during the third quarter worth $36,000. Finally, Covestor Ltd boosted its position in shares of LivaNova by 108.6% during the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after buying an additional 392 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.